Company / Shareholders' Equity
Spero Therapeutics, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$46.1M
FY2025
5-year range
$46.1M / $132.0M
FY2021-FY2025
Trend
-56.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 8 years, ranging from $46M in FY2025 to $132M in FY2021.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of -9.2%.
Declined from $76M to $46M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -19.5%
- 5-Year CAGR
- -9.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -9.2%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 56.9% year-over-year.
- Peak shareholders' equity was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $46.1M | -56.9% |
| FY2024 | $106.9M | +40.8% |
| FY2023 | $75.9M | -14.0% |
| FY2022 | $88.3M | -33.1% |
| FY2021 | $132.0M | +77.1% |
| FY2020 | $74.6M | +0.0% |
| FY2019 | $74.6M | -35.4% |
| FY2018 | $115.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026